Literature DB >> 29548874

New Regulatory Framework for Medical Devices in Japan: Current Regulatory Considerations Regarding Clinical Studies.

Akihide Konishi1, Soichiro Isobe2, Daisaku Sato3.   

Abstract

In Japan, a recent issue that required an urgent response was the streamlining of regulations concerning clinical trials of medical devices. On July 31, 2017, the Ministry of Health, Labour and Welfare enacted a new regulatory framework called the fast-break scheme for innovative medical devices aiming to expedite patient access while reducing the premarket regulatory burden of clinical trials and enhancing postmarketing commitments. The new framework is expected to provide greater benefits to patients who require access to new medical devices and to companies via improved transparency and predictability, as well as to reduce the social and medical cost incurred for medical innovation.
Copyright © 2017 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29548874     DOI: 10.1016/j.jvir.2017.12.022

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  3 in total

Review 1.  Electrophysiology devices and the regulatory approval process within the U.S. FDA and abroad.

Authors:  Kimberly A Selzman; Hetal Patel; Kenneth Cavanaugh
Journal:  J Interv Card Electrophysiol       Date:  2019-08-16       Impact factor: 1.900

2.  Comparison of supportive regulatory measures for pediatric medical device development in Japan and the United States.

Authors:  Sara Takahashi; Kiyotaka Iwasaki; Haruki Shirato; Mami Ho; Mitsuo Umezu
Journal:  J Artif Organs       Date:  2020-10-20       Impact factor: 1.731

3.  Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold.

Authors:  Akihide Konishi; Mami Ho; Yoshiaki Mitsutake; Takashi Ouchi; Masato Nakamura; Haruki Shirato
Journal:  Intern Med       Date:  2020-03-19       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.